Amer Zeidan: Global Disparities in Characteristics and Outcomes of Leukemia Clinical Trials
Amer Zeidan, Associate Professor of Medicine at Yale University, shared an article by Abdulrahman Alhajahjeh on X:
“Just in time for ASH24; our new paper from Yale Cancer Center and Yale Hematology group examined the Global Disparities in Characteristics & Outcomes of Leukemia Clinical Trials, led by rising star Abdulrahman Alhajahjeh.
We need more trials in developing countries.”
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.
Authors: Abdulrahman Alhajahjeh, et al.
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023